Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 61.42M | 59.63M | 50.23M | 46.85M | 42.21M | 26.89M |
Gross Profit | 30.39M | 29.86M | 25.32M | 26.02M | 23.23M | 14.92M |
EBITDA | -69.00M | -67.81M | -34.02M | -31.82M | -20.94M | -11.01M |
Net Income | -17.69M | -72.21M | -36.40M | -31.74M | -22.12M | -6.94M |
Balance Sheet | ||||||
Total Assets | 196.03M | 159.48M | 202.98M | 242.59M | 260.91M | 178.83M |
Cash, Cash Equivalents and Short-Term Investments | 124.31M | 69.60M | 145.68M | 188.42M | 224.07M | 159.23M |
Total Debt | 3.77M | 6.61M | 5.95M | 16.47M | 20.85M | 21.86M |
Total Liabilities | 36.60M | 44.88M | 37.49M | 51.99M | 46.30M | 39.79M |
Stockholders Equity | 159.42M | 114.59M | 165.49M | 190.60M | 214.60M | 139.04M |
Cash Flow | ||||||
Free Cash Flow | -35.77M | -30.85M | -27.10M | -22.98M | -29.82M | 4.12M |
Operating Cash Flow | -35.91M | -30.25M | -25.06M | -20.93M | -29.08M | 4.13M |
Investing Cash Flow | 9.77M | -46.32M | -26.40M | -15.81M | -737.00K | -9.00K |
Financing Cash Flow | 730.00K | -376.00K | -15.94M | 1.18M | 94.72M | 137.19M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $6.35B | 79.79 | 4.92% | 0.48% | 14.84% | -80.87% | |
62 Neutral | $2.49B | 30.62 | -19.69% | ― | 7.97% | -592.40% | |
56 Neutral | $232.38M | ― | -44.97% | ― | 21.06% | -99.70% | |
50 Neutral | $195.58M | ― | 271.41% | ― | 85.03% | 53.73% | |
49 Neutral | AU$2.48B | 4.33 | -64.25% | 2.85% | 36.51% | 13.14% | |
47 Neutral | $479.74M | ― | -29.16% | ― | 25.77% | 49.44% | |
46 Neutral | $108.29M | ― | -60.68% | ― | 19.84% | 5.77% |
On June 16, 2025, 908 Devices announced the appointment of Dr. Christopher D. Brown to its Board of Directors. Dr. Brown, a co-founder of 908 Devices and former Chief Technology Officer, brings extensive expertise in advanced analytical technologies. His return to the company is seen as a strategic move to leverage his vision and leadership, potentially enhancing the company’s technological advancements and market positioning.
The most recent analyst rating on (MASS) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on 908 Devices stock, see the MASS Stock Forecast page.
On June 12, 2025, 908 Devices Inc. held its Annual Meeting of Stockholders, where 70.8% of the company’s shares were represented. The meeting resulted in the election of Class II Directors and the ratification of PricewaterhouseCoopers LLP as the independent accounting firm for 2025, indicating a stable governance structure and continued financial oversight.
The most recent analyst rating on (MASS) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on 908 Devices stock, see the MASS Stock Forecast page.